Webinar: Traumatic Nerve Injury Platform & Innervated Skin.
Tuesday, March 19 (5:00 p.m. CET)
Overview.
Accidents, surgeries, and compressions (tumor, carpal canal syndrome) are examples of situations in which a traumatic injury to the spinal cord or nerves can induce neuropathic pain in addition to debilitating motor and sensory symptoms. Two main axes of treatments have an important impact on a patient's quality of life: (i) regenerative medicine to reconstruct and regenerate nerves and (ii) efficient pain relief.
To offer a translational nerve injury platform enabling the discovery of regenerative therapeutics we used the DuaLink™ Delta Ultra from the Neurofluidics™ line. The microchannel length between channel 2 and 3 (Figure 2) allows the monitoring of neurite regrowth after injury in channel 2. The DuaLink™ Shift architecture offers the same advantages obtained from the microchannels’ length (500 µm) and compatibility with MEA readouts. As a mirror of current in vivo models, such as nerve crush injury or nerve ligation that aim to mimic human nerve trauma, we created a repeatable and standardized injury, by cutting motor and sensory axons only using a short, targeted detergent application. Our devices' microfluidic isolation and architecture offer the advantage of targeting only neurites and not cell bodies like conventional in vitro models. We demonstrated the use of our platform by comparing axonal regeneration following treatment with a neurotrophic molecule or with a drug inhibiting neurite outgrowth.
Program.
• Introduction to DuaLink Shift NeuroFluidics Devices & PNS NeuroFluidics Cultures
• Use Case #1 - Motor and Sensory Nerve Injury Platform: Regrowth after trauma
• Paves the way to study complex cell communication during regenerative processes by adding glial cells (e.g. satellite cells, Schwann cells) or target organs (e.g. skin, muscle) and to develop a electrophysiological digital signature of axonal regrowth
• Introduction of DuaLink MEA & Skin NeuroFluidics Cultures
• Use Case #2 - Innervated skin: compartmentalized co-culture of primary keratinocytes & hiPSC-derived sensory neurons
• Q&A
Tuesday March 19 (5:00 p.m. CET)
Speakers.
About Hélène Gautier.
Hélène Gautier, PhD in Neurosciences, is Product Owner Organ-on-chip leading the R&D development of PNS & Pain platforms at NETRI. She has 19 years of laboratory expertise in ion channel biology, electrophysiology and imaging, studying the mode of action of chemicals or biological functions. From in vitro to in vivo, she developed low to high-throughput functional assays, to understand new physiological mechanisms and drugs mode of action & toxicity, from the target to the biological effect. Hélène joined NETRI in 2022 and has a strong academic background and 7 years experience in the private sector at key steps of drug development.
About Alexandre Guichard.
Alexandre Guichard is a pharmacist (PharmD.) and a researcher (PhD) specialized in clinical and research dermatology. He was trained at Besançon University Hospital as a resident in the Department of Dermatology led by Pr HUMBERT. He specialized in dermatology, trichology, and skin biometrology. After having led the clinical trials of a Swiss company for 6 years, Alexandre joined NETRI in June 2022. As a Product Owner at NETRI, he is in charge of creating new architectures and new models of organ-on-chip in the field of dermo cosmetology.
